A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

Korábbi kezelés

• Prior transplant of any organ (including BM and stem cell transplant) or kidney transplant scheduled in the next 6 months.
• Acute coronary syndrome, stroke or TIA or hospitalization for heart failure in previous 12 weeks or poorly controlled hypertension (≥160/100 mmHg at screening visit) or SBP<90 at screening visit.
• On medications such as immunosuppressant, monoclonal antibodies, anabolic steroids, at the time of screening or in the previous 6 months and/or illicit drugs.
• History of alcohol abuse or cigarette smoking in the previous 6 months.
• Panel Reactive Antibodies (PRA) >0% (positive)

Más betegség

• History of malignancy (except successfully treated squamous and basal cells skin carcinoma) within 5 years of screening.
• History of atrial fibrillation (AF, AFib).
• CKD due to genetic disorder.
• History of systemic Autoimmune diseases like T1D, SLE or CKD caused by any autoimmune kidney disease.
• Dialysis for acute renal failure within 12 weeks of screening visit.
• Disorder of coagulation (including any history of thrombotic or thromboembolic disease) and/or long-term anti-coagulant therapy
• History of Deep Vein Thrombosis (DVT)
• History of Acute Pulmonary Embolism
• History of solitary kidney.
• Presence of any active infection, including COVID 19
• Any clinically significant pulmonary disease
• History of hypersensitivity to study drug and/or any of its excipients.

Laborértékek

• Proteinuria>5000 and or serum Albumin< 2.5 g/dl.
• Acute Kidney Injury (AKI) defined as increase in serum creatinine ≥1.5 times baseline in the previous 3 months or by presence of acute tubular injury in kidney biopsy in the previous 3 months.
• Rapidly progressive kidney disease (eGFR reduction ≥ 30% over the last three months)
• HbA1c ≥ 8.5%.
• History of liver disease, ALT and AST ≥3 x ULN, positive serology for Hepatitis B or Hepatitis C, HIV.

Egyéb

• Participants are excluded from the study if any of the following criteria apply:
• BMI ≥35 kg/m2.
• Pregnancy or breast feeding at the time of screening, or with intention to become pregnant or breast-feeding during the course of the study, including the follow-up period.
• A significant medical history or abnormality at the physical exam that, in the judgment of the principal investigator, may interfere with the study.
• Close affiliation with the investigational site; for example, a close relative of the investigator, dependent person (for example employee or student of the investigational site).

• Participants are eligible to be included in the study only if all of the following criteria apply:
• Patient is able to communicate well with the investigator, is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, understands all requirements of the study, and understands and signs the written ICF before any study-specific procedure.
• Willing and able to comply with the scheduled visits and treatment plan.
• Either biological sex
• Participant must be 35 to 75 years of age inclusive, at the time of signing the informed consent.
• Diagnosis of CKD stage 3, G3 (a and b): persistent eGFR between 30 and 59 mL/min/1.73 m² (at least 2 measures within that range in the preceding 3 months, including the one at screening visit), and persistent increased Albuminuria (at least 2 measures within 3 months, including 1 before screening and 1 at screening (criterion for increased Albuminuria at screening: ≥2 out of 3 repeat daily early morning samples at screening) (UACR ≥ 200 mg/g and < than 5000 mg/g)
• Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), and SGLT2 inhibitors (SGLT2i) unless such treatment is contraindicated or not tolerated*. Treatment dose must be stable for at least 3 months prior to the date of the screening. If a patient is on treatment with GLP-1 receptor agonist, he/she should be on a stable dose for at least 3 months before screening.
  • *Participants who are documented to be unable to take ACE inhibitors or ARBs or SGLT2i will be allowed to participate.
• Female subjects must not be breastfeeding and must have no intention to become pregnant during the study, and she will be required to use at least two FDA approved birth control during the study. The FDA-approved and cleared methods for birth control are listed below:
  • Permanent Sterilization
  • Long-Acting Reversible Contraceptives (LARC)
  • Contraceptive Injection
  • Short-Acting Hormonal Methods
  • Barrier Methods
  • Emergency Contraception
• Any male subject must agree to use contraceptives and not donate sperm during the study.
• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.